2-溴-4H-呋喃并[3,2-B]吡咯-5-羧酸 | 332099-11-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 呋喃吡咯
• 中文名称: 2-溴-4H-呋喃并[3,2-B]吡咯-5-羧酸
• 中文别名: 2-溴-4H-呋喃并[3,2-b]吡咯-5-羧酸
• 英文名称: 2-Bromo-4H-furo[3,2-b]pyrrole-5-carboxylic acid
• CAS: 332099-11-3
• 化学式: C₇H₄BrNO₃
• 分子量: 230.018
• InChiKey: WZMNTSZIYSQDAN-UHFFFAOYSA-N

物化性质

• 沸点：
  438.2±40.0 °C(Predicted)
• 密度：
  2.028

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  66.2
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  2-溴-4H-呋喃并[3,2-B]吡咯-5-羧酸 、 2,4-二氯苯硼酸 在 四(三苯基膦)钯 、 sodium carbonate 作用下， 以 水 、 乙腈 为溶剂， 生成 2-(2,4-dichlorophenyl)-4H-furo[3,2-b]pyrrole-5-carboxylic acid
  参考文献：
  名称：

  The discovery of fused pyrrole carboxylic acids as novel, potent d-amino acid oxidase (DAO) inhibitors

  摘要：

  The 'NMDA hypofunction hypothesis of schizophrenia' can be tested in a number of ways. DAO is the enzyme primarily responsible for the metabolism of d-serine, a co-agonist for the NMDA receptor. We identified novel DAO inhibitors, in particular, acid 1, which demonstrated moderate potency for DAO in vitro and ex vivo, and raised plasma d-serine levels after dosing ip to rats. In parallel, analogues were prepared to survey the SARs of 1.

  DOI：

  10.1016/j.bmcl.2008.04.020
• 作为产物：
  描述：

  methyl 2-bromo-4H-furo[3,2-b]pyrrole-5-carboxylate 在 sodium hydroxide 作用下， 生成 2-溴-4H-呋喃并[3,2-B]吡咯-5-羧酸
  参考文献：
  名称：

  The discovery of fused pyrrole carboxylic acids as novel, potent d-amino acid oxidase (DAO) inhibitors

  摘要：

  The 'NMDA hypofunction hypothesis of schizophrenia' can be tested in a number of ways. DAO is the enzyme primarily responsible for the metabolism of d-serine, a co-agonist for the NMDA receptor. We identified novel DAO inhibitors, in particular, acid 1, which demonstrated moderate potency for DAO in vitro and ex vivo, and raised plasma d-serine levels after dosing ip to rats. In parallel, analogues were prepared to survey the SARs of 1.

  DOI：

  10.1016/j.bmcl.2008.04.020

文献信息

• Use of glycogen phosphorylase inhibitors
  申请人：——

  公开号：US20030004162A1

  公开（公告）日：2003-01-02

  The invention provides methods of treating prophylactically an individual in whom Type 2 diabetes mellitus has not yet presented, but in whom there is an increased risk of developing such condition, which methods comprise administering to an individual in need thereof an effective amount of a glycogen phosphorylase inhibitor; effective amounts of a glycogen phosphorylase inhibitor and a non-glycogen phosphorylase inhibiting anti-diabetic agent; or effective amounts of a glycogen phosphorylase inhibitor and an anti-obesity agent. The invention further provides methods of treating prophylactically an individual in whom Type 2 diabetes mellitus has not yet presented, but in whom there is an increased risk of developing such condition, which methods comprise administering to an individual in need thereof a pharmaceutical composition comprising effective amounts of a glycogen phosphorylase inhibitor and a non-glycogen phosphorylase inhibiting anti-diabetic agent; or effective amounts of a glycogen phosphorylase inhibitor and an anti-obesity agent.

  本发明提供了一种预防性地治疗尚未出现2型糖尿病但存在发展为该病风险的个体的方法，该方法包括向需要该方法的个体施用有效量的糖原磷酸化酶抑制剂；有效量的糖原磷酸化酶抑制剂和非糖原磷酸化酶抑制的抗糖尿病剂；或者有效量的糖原磷酸化酶抑制剂和抗肥胖剂。本发明还提供了一种预防性地治疗尚未出现2型糖尿病但存在发展为该病风险的个体的方法，该方法包括向需要该方法的个体施用包含有效量的糖原磷酸化酶抑制剂和非糖原磷酸化酶抑制的抗糖尿病剂的药物组合物；或者有效量的糖原磷酸化酶抑制剂和抗肥胖剂。
• FLUORO-SUBSTITUTED INHIBITORS OF D-AMINO ACID OXIDASE
  申请人：Heffernan L. R. Michele

  公开号：US20080004327A1

  公开（公告）日：2008-01-03

  This invention provides novel inhibitors of the enzyme D-amino acid oxidase as well as pharmaceutical compositions including the compounds of the invention. The invention also provides methods for the treatment and prevention of neurological disorders, such as neuropsychiatric and neurodegenerative diseases, as well as pain, ataxia and convulsion. The compounds of the invention have the general structure: wherein A is NH or S. Q is a member selected from CR 1 and N. X and Y are members independently selected from O, S, CR 2 , N and NH. R 1 , R 2 and R 4 are members independently selected from H and F, provided that at least one member selected from R 1 , R 2 and R 4 is F. R 6 is a member selected from O − X + and OH, wherein X + is a positive ion, which is a member selected from inorganic positive ions and organic positive ions.

  这项发明提供了D-氨基酸氧化酶的新型抑制剂，以及包括该发明中化合物的药物组合物。该发明还提供了用于治疗和预防神经系统疾病，如神经精神病和神经退行性疾病，以及疼痛、共济失调和抽搐的方法。该发明中的化合物具有一般结构：其中A为NH或S。Q是从CR1和N中选择的成员。X和Y分别是从O、S、CR2、N和NH中独立选择的成员。R1、R2和R4是从H和F中独立选择的成员，前提是至少选择R1、R2和R4中的一个成员为F。R6是从O−X+和OH中选择的成员，其中X+是正离子，从无机正离子和有机正离子中选择的成员。
• Tetrazole compounds as thyroid receptor ligands
  申请人：——

  公开号：US20020006946A1

  公开（公告）日：2002-01-17

  The present invention relates to tetrazole compounds of Formula I, stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, and pharmaceutically acceptable salts of the prodrugs. 1 The invention also relates to compositions comprising the tetrazole compounds and to methods of treating obesity, diabetes, atherosclerosis, hypertension, coronary heart disease, hypercholesterolemia, hyperlipidemia, thyroid disease, thyroid cancer, hypothyroidism, depression, glaucoma, cardiac arrhythmias, congestive heart failure, and osteoporosis using the tetrazole compounds.

  本发明涉及公式I的四唑化合物、立体异构体、药用可接受的盐及其前药，以及前药的药用可接受的盐。该发明还涉及包含四唑化合物的组合物，以及使用四唑化合物治疗肥胖、糖尿病、动脉粥样硬化、高血压、冠心病、高胆固醇血症、高脂血症、甲状腺疾病、甲状腺癌、甲状腺功能减退症、抑郁症、青光眼、心律失常、充血性心力衰竭和骨质疏松症的方法。
• Methods of treating diabetic cardiomyopathy using glycogen phosphorylase inhibitors
  申请人：——

  公开号：US20010046958A1

  公开（公告）日：2001-11-29

  The present invention provides methods of treating diabetic cardiomyopathy, the methods comprising administering to a patient having or at risk of having diabetic cardiomyopathy a therapeutically effective amount of a glycogen phosphorylase inhibitor. The present invention also provides methods of treating diabetic cardiomyopathy, the methods comprising administering to a patient having 1) diabetes and 2) having cardiovascular disease, ischemic heart disease, congestive heart failure, congestive heart failure but not having coronary arteriosclerosis, hypertension, diastolic blood pressure abnormalities, microvascular diabetic complications, abnormal left ventricular function, myocardial fibrosis, abnormal cardiac function, pulmonary congestion, small vessel disease, small vessel disease without atherosclerotic cardiovascular disease or luminal narrowing, coagulopathy, cardiac contusion, or having had or at risk of having a myocardial infarction a therapeutically effective amount of a glycogen phosphorylase inhibitor.

  本发明提供了治疗糖尿病心肌病的方法，该方法包括向患有或有患糖尿病心肌病风险的患者施用治疗有效量的糖原磷酸化酶抑制剂。本发明还提供了治疗糖尿病心肌病的方法，该方法包括向同时患有1）糖尿病和2）心血管疾病、缺血性心脏病、充血性心力衰竭、充血性心力衰竭但不患冠状动脉硬化、高血压、舒张期血压异常、微血管糖尿病并发症、左心室功能异常、心肌纤维化、心脏功能异常、肺充血、小血管病变、无动脉粥样硬化性心血管疾病或腔内狭窄的小血管病变、凝血异常、心脏挫伤或有心肌梗死风险的患者施用治疗有效量的糖原磷酸化酶抑制剂。
• Methods of treating obesity using a neurotensin receptor ligand
  申请人：——

  公开号：US20010046956A1

  公开（公告）日：2001-11-29

  The present invention relates to methods of treating obesity, diabetes, sexual dysfunction, atherosclerosis, insulin resistance, impaired glucose tolerance, hypercholesterolemia or hypertrigylceridemia using a neurotensin receptor ligand. The present invention also relates to pharmaceutical compositions and kits that comprise a neurotensin receptor ligand.

  本发明涉及使用神经肽T受体配体治疗肥胖症、糖尿病、性功能障碍、动脉粥样硬化、胰岛素抵抗、糖耐量受损、高胆固醇血症或高三酰甘油血症的方法。本发明还涉及包含神经肽T受体配体的制药组合物和工具箱。